Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04961528
Other study ID # APHP200043
Secondary ID 2020-005931-58PH
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 27, 2022
Est. completion date January 31, 2026

Study information

Verified date May 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Karine Goude-Ory
Phone 01 44 84 17 22
Email karine.goude@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims is to verify the hypothetize that inhaled Tranexamic Acid (TXA) or Terlipressin (TER) will be associated with an increase in the rapid control of hemoptysis without side-effects. This randomized double-blind multicenter triple arm trial compares the administration of TXA to TER to placebo in patients with mild to severe hemoptysis.


Description:

In over 90% of cases, hemoptysis is due to a bronchial or non-bronchial systemic arterial mechanism. Embolization of Bronchial Arteries (EBA) is the main specific treatment but is not easily available. Medical treatment for hemoptysis is not evidence-based. For this study, the investigators will dispense trial drugs using inhalation route which has not been evaluated in mild to severe hemoptysis in previous trials. In addition, as opposed to previous trials, the investigators will assess the safety of trials drugs during hospital stay. Acid tranexamic (TXA), an antifibrinolytic drug, reduces bleeding in uterine and traumatic haemorrhage by blocking the action of plasmin on fibrin. Intravenous terlipressin (TER), a vasoconstrictor, contributes to control digestive haemorrhage but presents many contraindication when administrated by intravenous route. The investigator hypothetize that inhaled antifibrinolytic (TXA) or vasoconstrictor (TER) will be associated with an increase in the rapid control of hemoptysis without side-effects. Patients will be randomized into 3 groups: - Active treatment 1: Tranexamic Acid 500 mg three times a day (every 8 hours) for 5 days. - Active treatment 2: Terlipressin 1 mg three times a day (every 8 hours) for 5 days. - Placebo: normal saline nebulization three times a day (every 8 hours) for 5 days. Using a hierarchical analysis, the comparison between TXA and TER will be tested once superiority on efficacy of both inhaled TXA and TER vs placebo is demonstrated. The above secondary objectives will then be assessed for the comparison of TXA versus TER.


Recruitment information / eligibility

Status Recruiting
Enrollment 315
Est. completion date January 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Patients over 18 years, under 90 years - Mild to severe hemoptysis that has been going on for less than 7 days - Total expectorate blood ranging from 50 ml to 200 ml - Admission in emergency department or ICU for less than 12 hours - Social security affiliation - Signed informed consent - For child-bearing aged women, efficient contraception includes oral oestrogen- progestin, oral progestin, progestin implants and all types of intrauterine devices Exclusion Criteria: - Need for mechanical ventilation - Cystic fibrosis - Pregnancy or breast feeding - Contraindication for contrast agents injection (renal failure with creatinin clearance < 30mL/min, know allergy to contrast agents injection) - Known hypersensitivity to TXA or TER or one of its excipients - Know previous cardiac arrhythmia (atrial fibrillation, atrial flutter..) - Contraindication to TXA (including renal failure with creatinin clearance < 30mL/min) or TER therapy : - acute myocardial infarction in the 6 past months, - intrathecal injection in the 3 past months, - seizure in the past 3 months - Participation in another interventional study or being in the exclusion period at the end of a previous study. - Patient under tutorship or / guardianship, and incapable to give informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tranexamic Acid 500 MG
Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient). The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 3 days
Terlipressin
Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient). The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 3 days
Placebo
Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient). The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days.

Locations

Country Name City State
France AP-HP, Hôpital Européen Georges Pompidou Paris

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Ministry of Health, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with complete or partial resolution of hemoptysis without the use of any interventional procedure. Efficacy of inhaled tranexamic acid and inhaled terlipressin versus placebo (normal saline) in immediate control of mild to severe hemoptysis within the first 3 days of hospitalization.
A complete resolution of hemoptysis is defined by absence of recurrence within 3 days; partial resolution is defined as hemoptysis recurrence < 50 ml within the first 3 days
3 days
Secondary Rate of complete resolution of hemoptysis within 3 days, as previously defined Complete resolution of hemoptysis, as previously defined 3 days
Secondary Rate of partial resolution of hemoptysis defined as recurrence < 50 ml Partial resolution of hemoptysis, as previously defined 3 days
Secondary Rate of patients with total volume of hemoptysis < 200 ml Total volume of hemoptysis < 200 ml 3 days
Secondary Rate of patients who need an endovascular treatment (bronchial arterial endovascular embolization) Need of invasive procedure such as bronchial arterial endovascular embolization 3 days
Secondary Time between hospital admission and bronchial arterial endovascular embolization Time between hospital admission and endovascular treatment 3 days
Secondary Rate of patients who need a mechanical ventilation Need of invasive procedure such as mechanical ventilation, 3 days
Secondary Rate of specific adverse events Specific Adverse Events (AE) : acute myocardial ischemia, symptomatic venous thromboembolism, hyponatremia (<130 mmol/L), bronchospasm (defined by the need of short-acting bronchodilatator). 3 days
Secondary Rate of in-hospital mortality 30 days
Secondary Rate of patients with hemoptysis recurrence 30 days
Secondary Death rate 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT02913365 - Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis N/A
Completed NCT00387374 - Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab Phase 2
Completed NCT05513248 - Perioperative Outcomes of Anatomic Lung Resections in Patients Who Recovered From Coronavirus Disease 2019
Recruiting NCT05634200 - Utility of Bronchoscopy in Patients With Haemoptysis and Negative Chest CT Scan
Recruiting NCT05554731 - Development and Application of a New Balloon Catheter for Intraairway Hemostasis N/A
Recruiting NCT06144398 - Single Use Flexible Bronchoscopes in Interventional Pulmonary Procedures N/A
Completed NCT01278199 - Bronchial Artery Embolization and Medical Measures in Non Severe Acute Hemoptysis of Mild-moderate Abundance N/A
Recruiting NCT05786781 - An Exploratory Study on the Application of Transarterial CT Angiography in the Interventional Treatment of Hemoptysis N/A
Completed NCT04087135 - Comparison of Intubation With Direct Laryngoscopy or Videolaryngoscopy in an Hemoptysis Simulated Situation on Human Cadaver Embalmed With Thiel's Method N/A
Recruiting NCT03270735 - A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase Injection Phase 4
Completed NCT00929565 - Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy N/A
Completed NCT01171768 - The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis N/A
Withdrawn NCT01167764 - Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis Phase 3
Completed NCT03126968 - Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies Phase 2/Phase 3
Completed NCT02781597 - Efficacy of Tranexamic Acid in Hemoptysis Phase 3
Recruiting NCT05648656 - TXA Nebulization for the Treatment of Hemoptysis Phase 3
Completed NCT04771923 - Tranexamic Acid Versus Adrenaline for Controlling Iatrogenic Endobronchial Bleeding N/A
Recruiting NCT06145191 - Prophylactic Tranexamic Acid Versus Adrenaline During Flexible Bronchoscopy N/A
Completed NCT04770675 - Post Market Study to Collect Data for Software Recognizing the Anatomical Structures During Bronchoscopy.
Completed NCT06067997 - Prevalence Of Pulmonary Embolism In Patients With HEmoptysis (POPEIHE)